Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-kappa B-dependent signaling and glucose consumption

Full text
dos-Santos-Pereira, Mauricio [1, 2, 3] ; Guimaraes, Franscisco S. [1, 4] ; Del-Bel, Elaine [1, 2] ; Raisman-Vozari, Rita [3] ; Michel, Patrick P. [3]
Total Authors: 5
[1] Univ Sao Paulo, NAPNA, Sao Paulo - Brazil
[2] Univ Sao Paulo, Dept Morfol Fisiol & Patol Basica, Fac Odontol, Ribeirao Preto - Brazil
[3] Sorbonne Univ, Inst Cerveau & Moelle Epiniere ICM, CNRS, INSERM, UMR 7225, U1127, Paris - France
[4] Univ Sao Paulo, Dept Farmacol, Fac Med, Ribeirao Preto - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Glia; v. 68, n. 3, p. 561-573, MAR 2020.
Web of Science Citations: 0

We used mouse microglial cells in culture activated by lipopolysaccharide (LPS, 10 ng/ml) to study the anti-inflammatory potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis. Under LPS stimulation, CBD (1-10 mu M) potently inhibited the release of prototypical proinflammatory cytokines (TNF-alpha and IL-1 beta) and that of glutamate, a noncytokine mediator of inflammation. The effects of CBD were predominantly receptor-independent and only marginally blunted by blockade of CB2 receptors. We established that CBD inhibited a mechanism involving, sequentially, NADPH oxidase-mediated ROS production and NF-kappa B-dependent signaling events. In line with these observations, active concentrations of CBD demonstrated an intrinsic free-radical scavenging capacity in the cell-free DPPH assay. Of interest, CBD also prevented the rise in glucose uptake observed in microglial cells challenged with LPS, as did the inhibitor of NADPH oxidase apocynin and the inhibitor of I kappa B kinase-2, TPCA-1. This indicated that the capacity of CBD to prevent glucose uptake also contributed to its anti-inflammatory activity. Supporting this view, the glycolytic inhibitor 2-deoxy-d-glucose (2-DG) mimicked the antioxidant/immunosuppressive effects of CBD. Interestingly, CBD and 2-DG, as well as apocynin and TPCA-1 caused a reduction in glucose-derived NADPH, a cofactor required for NADPH oxidase activation and ROS generation. These different observations suggest that CBD exerts its anti-inflammatory effects towards microglia through an intrinsic antioxidant effect, which is amplified through inhibition of glucose-dependent NADPH synthesis. These results also further confirm that CBD may have therapeutic utility in conditions where neuroinflammatory processes are prominent. (AU)

FAPESP's process: 18/03482-0 - The action of cannabinoid drugs in glial-derived neuroinflammation process: a link to L-dopa-induced dyskinesia
Grantee:Maurício dos Santos Pereira
Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
FAPESP's process: 14/25029-4 - Contribution of the neuroinflamation to L-DOPA induced dyskinesia
Grantee:Elaine Aparecida Del Bel Belluz Guimarães
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 17/14207-7 - The action of cannabinoid drugs in L-dopa-induced dyskinesia: analysis of neuroinflammation and glutamate release in glial cells
Grantee:Maurício dos Santos Pereira
Support Opportunities: Scholarships in Brazil - Post-Doctoral